Tag: Pharnext
PHARNEXT: Information relating to the total number of voting rights and shares making up the share capital and the par value of the shares – 01/12/2023 at 6:00 p.m.
PARIS, France, 1 er December 2023 at 6 p.m. (CET) – Pharnext SCA (FR001400JXB0 – ALPHA) (the “Company”), a biopharmaceutical company at an advanced clinical stage developing new therapies for…
PHARNEXT: Fundraising of 0.5 million euros – 11/24/2023 at 8:00 p.m.
PARIS, France, November 24, 2023 at 8 p.m. (CET) – Pharnext SCA (FR001400JXB0 – ALPHA) (the “Company”), an advanced clinical stage biopharmaceutical company developing new therapies for neurodegenerative diseases without…
Pharnext has successfully manufactured its PXT3003 product in the United States – 11/20/2023 at 10:10 a.m.
(AOF) – Pharnext announces that it has successfully manufactured registration batches of PXT3003 in the United States. The biotech developing new therapies for neurodegenerative diseases specifies that this success was…
Pharnext: the title rises, a step taken in the USA – 11/20/2023 at 11:07
(CercleFinance.com) – Pharnext climbed more than 14% on Monday on the Paris Stock Exchange after successfully manufacturing registration batches of its experimental treatment against Charcot’s disease in the United States.…
PHARNEXT: Adjustment of the nominal value – 11/13/2023 at 08:30
PARIS, France, November 13, 2023 at 8:30 a.m. (CET) – Pharnext SCA (FR001400JXB0 – ALPHA) (the “Company”), an advanced clinical stage biopharmaceutical company developing new therapies for neurodegenerative diseases without…
Pharnext: offer for its drug candidate in Charcot-Marie-Tooth disease type 1A
(AOF) – Pharnext, an advanced clinical stage biopharmaceutical company developing new therapies for neurodegenerative diseases, announced that it has received a non-binding offer with a view to signing an agreement…
Pharnext: new offer from a ‘top 10’ player
(CercleFinance.com) – Pharnext announced on Monday that it had received a new offer from a ‘top’ 10 global laboratory valuing its drug candidate for Charcot’s disease at more than 500…
PHARNEXT: Pharnext receives a new offer valuing its drug candidate in Charcot-Marie-Tooth disease type 1A at more than 500 MEUR and the support of its financial partners – 10/30/2023 at 08:30
PARIS, France, October 30, 2023 at 8:30 a.m. (CET) – Pharnext SCA (FR001400JXB0 – ALPHA) (the “Company”), an advanced clinical stage biopharmaceutical company developing new therapies for neurodegenerative diseases without…
PHARNEXT: Fundraising of 2 million euros – 10/27/2023 at 8:00 p.m.
PARIS, France, October 27, 2023 at 8 p.m. (CET) – Pharnext SCA (FR001400JXB0 – ALPHA) (the “Company”), an advanced clinical stage biopharmaceutical company developing new therapies for neurodegenerative diseases without…
PHARNEXT: Adjustment of the nominal value – 10/24/2023 at 9:00 p.m.
PARIS, France, October 24, 2023 at 9 p.m. (CET) – Pharnext SA (FR001400JXB0 – ALPHA) (the “Company”), an advanced clinical stage biopharmaceutical company developing new therapies for neurodegenerative diseases without…
Néovacs: Boosted on the stock market by the Pharnext file
(CercleFinance.com) – With gains of 33%, Néovacs shares topped the biggest gains on the Paris market on Monday, boosted by the prospect of a major contract for its subsidiary Pharnext.…
Néovacs: boosted on the stock market by the Pharnext file
(CercleFinance.com) – With gains of 33%, Néovacs shares topped the biggest gains on the Paris market on Monday, boosted by the prospect of a major contract for its subsidiary Pharnext.…